AEON Biopharma (AEON) via Priveterra Acq (PMGM) deck
AEON is a clinical stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets.
This post is for subscribers onlySubscribe
Already have an account? Log in